NK cells from BC patients are less responsive to cytokine activation and display a reduced lytic activity, especially against CSCs, due to the low expression of NCRs and CD62L, crucial for recognition and killing of target cells, and by the presence of immature CD57− NK cells. This evidence concerns the gene SELL and breast cancer.